Skip to main content

Advertisement

Table 3 MASES, tender joint count, and swollen joint count by sex, HLA-B27 positivity, and concomitant DMARD use

From: Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis

  All Male Female HLA-B27-negative HLA-B27-positive No concomitant DMARD at baseline Concomitant DMARD at baseline
  Median
First quartile, third quartile
[95% confidence interval]
Patients with enthesitis, MASES ≥ 1 at baseline
MASES: 0 to 13, number (percentage) 667
(100)
431
(64.6)
236
(35.4)
126
(18.9)a
523
(78.4)a
499
(74.8)
168
(25.2)
Baseline 5
2, 8
4
2, 7
7
4, 9
5
2, 9
5
2, 8
5
2, 8
4
2, 8
Week 12 1
0, 4
0
0, 2
1
0, 5
1
0, 5
0
0, 3
0
0, 3
1
0, 4
Change from baseline to week 12 -2
-5,-1
[-3 to -2]
-2
-5,-1
[-3 to -2]
-3
-6,-1
[-4 to -2]
-2
-5,-1
[-3 to -2]
-3
-6,-1
[-3 to -2]
-3
-5,-1
[-3 to -2]
-2
-5,-1
[-5 to -2]
Patients with peripheral arthritis, SJC ≥ 1 at baseline
TJC: 0 to 46, number (percentage) 281
(100)
175
(62.2)
106
(37.7)
57
(20.3)a
217
(77.2)a
170
(60.5)
111
(39.5)
Baseline 5
2, 12
4
2, 10
7
3, 14
6
3, 13
5
2, 12
4
2, 10
6
3, 13
Week 12 1
0, 3
1
0, 3
1
0, 4
1
0, 4
0
0, 3
0
0, 3
1
0, 4
Change from baseline to week 12 -3
-8,-1
[-4 to -2]
-2
-6,-1
[-3 to -2]
-4
-10,-2
[-6 to -3]
-3
-10,-1
[-6 to -2]
-3
-7,-1
[-4 to -2]
-2
-7,-1
[-3 to -2]
-3
-9,-2
[-4 to -2]
SJC: 0 to 44, number (percentage) 281
(100)
175
(62.2)
106
(37.7)
57
(20.3)a
217
(77.2)a
170
(60.5)
111
(39.5)
Baseline 2
1, 4
2
1, 3
2
1, 6
2
1, 6
2
1, 4
2
1, 3
2
1, 6
Week 12 0
0, 1
0
0, 1
0
0, 1
0
0, 1
0
0, 1
0
0, 1
0
0, 1
Change from baseline to week 12 -1
-3,-1
[-2 to -1]
-1
-3,-1
[-2 to -1]
-2
-4,-1
[-2 to -1]
-1
-4,-1
[-2 to -1]
-1
-3,-1
[-2 to -1]
-1
-2,-1
[-1 to -1]
-2
-4,-1
[-2 to -2]
  1. aBecause of missing data, the percentages of patients with HLA-B27 status do not sum to 100%. DMARD, disease-modifying antirheumatic drug; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; SJC, swollen joint count; TJC, tender joint count.